F Dentali1, M Gianni, G Agnelli, W Ageno. 1. Department of Clinical Medicine, University of Insubria, Varese, Italy. fdentali@libero.it
Abstract
BACKGROUND: The risk of deep vein thrombosis (DVT) is increased in cancer patients with central venous catheters (CVC). Factor (F)V Leiden and the G20210A prothrombin mutation (PTM) may play a role in causing catheter-related DVT in patients with cancer. However, information on the association between these thrombophilic abnormalities and CVC-related thrombosis are scarce. PURPOSE: To assess the risk of CVC-related thrombosis associated with these two thrombophilic disorders. METHODS: MEDLINE and EMBASE databases (up to March 2007); reference lists of retrieved articles. Studies comparing the prevalence of prothrombotic abnormalities in cancer patients with CVC-related thrombosis and in a control group of cancer subjects with CVC without thrombosis. Two reviewers independently selected studies and extracted study characteristics, quality and outcomes. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for each trial and pooled. RESULTS: Ten studies involving 1000 patients were included. The pooled OR for CVC-related thrombosis was 4.6 (95% CI: 2.6, 8.1) in patients with FV Leiden. The pooled OR for CVC-related thrombosis was 4.9 (95% CI: 1.7, 14.3) in patients with PTM. The estimated attributable risk of CVC-related thrombosis was 13.1% for FV Leiden and 4.5% for PTM. CONCLUSION: Our meta-analysis suggests that the presence of FV Leiden and PTM is associated with CVC-related thrombosis.
BACKGROUND: The risk of deep vein thrombosis (DVT) is increased in cancerpatients with central venous catheters (CVC). Factor (F)V Leiden and the G20210A prothrombin mutation (PTM) may play a role in causing catheter-related DVT in patients with cancer. However, information on the association between these thrombophilic abnormalities and CVC-related thrombosis are scarce. PURPOSE: To assess the risk of CVC-related thrombosis associated with these two thrombophilic disorders. METHODS: MEDLINE and EMBASE databases (up to March 2007); reference lists of retrieved articles. Studies comparing the prevalence of prothrombotic abnormalities in cancerpatients with CVC-related thrombosis and in a control group of cancer subjects with CVC without thrombosis. Two reviewers independently selected studies and extracted study characteristics, quality and outcomes. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for each trial and pooled. RESULTS: Ten studies involving 1000 patients were included. The pooled OR for CVC-related thrombosis was 4.6 (95% CI: 2.6, 8.1) in patients with FV Leiden. The pooled OR for CVC-related thrombosis was 4.9 (95% CI: 1.7, 14.3) in patients with PTM. The estimated attributable risk of CVC-related thrombosis was 13.1% for FV Leiden and 4.5% for PTM. CONCLUSION: Our meta-analysis suggests that the presence of FV Leiden and PTM is associated with CVC-related thrombosis.
Authors: Ambarina S Faiz; Imran Khan; Michele G Beckman; Paula Bockenstedt; John A Heit; Roshni Kulkarni; Marilyn Manco-Johnson; Stephan Moll; Thomas L Ortel; Claire S Philipp Journal: Thromb Res Date: 2015-07-05 Impact factor: 3.944
Authors: Mario Enrico Canonico; Ciro Santoro; Marisa Avvedimento; Giuseppe Giugliano; Giulia Elena Mandoli; Maria Prastaro; Anna Franzone; Raffaele Piccolo; Federica Ilardi; Matteo Cameli; Giovanni Esposito Journal: Biomolecules Date: 2022-02-04